ALDX STOCK NOTIFICATION: Did Aldeyra Therapeutics, Inc. Violate the Securities Laws? Investors are Notified to Contact BFA Law (NASDAQ:ALDX)

Core Viewpoint - Aldeyra Therapeutics, Inc. is under investigation for potential violations of federal securities laws following the failure of its lead drug candidate, reproxalap, to demonstrate efficacy in treating dry eye disease, leading to a significant stock price decline [1][4][5]. Company Overview - Aldeyra Therapeutics is a biotechnology company focused on developing therapies for immune-mediated and metabolic diseases, with reproxalap as its lead drug candidate aimed at treating dry eye disease [2]. Clinical Trial Results - The company announced success in its Phase III clinical trial for reproxalap, claiming the results were "uniquely supportive" and met FDA requirements for New Drug Application (NDA) resubmission [3]. - However, the trial ultimately failed to demonstrate the drug's efficacy, with methodological issues identified, including differences in baseline scores across treatment arms, which did not satisfy FDA requirements [4]. Stock Market Reaction - Following the FDA's issuance of a Complete Response Letter stating that the NDA for reproxalap failed to demonstrate efficacy, Aldeyra's stock price plummeted nearly 75% in a single trading day, dropping from $5.33 per share on April 2, 2025 [5].